https://www.selleckchem.com/pr....oducts/nazartinib-eg
Multivariate analysis revealed that revision ACLR was significantly related only to age 25years (OR 6.25; 95% CI 3.57-11.11; P 0.001), time from injury to surgery 12months (OR 2.27; 95% CI 1.25-4.17; P = 0.007) and quadriceps strength LSI of ≥ 90% (OR 1.70; 95% CI 1.16-2.49; P = 0.006). Age 25years, time from injury to surgery 12months and 6-month quadriceps strength LSI of ≥ 90% increased the odds of revision ACLR within 2years of primary ACLR. Understanding the risk factors for revision ACLR
Like
Comment
Share
